Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about apoe: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
Apolipoprotein E (APOE) is the primary cholesterol carrier in the brain, essential for lipid transport, neuronal repair, and synaptic maintenance. The APOE gene has three common alleles: APOE2, APOE3, and APOE4. APOE4 is the strongest genetic risk factor for late-onset Alzheimer's disease, increasing risk 3-15 fold depending on copy number. APOE4 impairs amyloid-beta clearance, promotes neuroinflammation, disrupts blood-brain barrier integrity, and reduces cerebrovascular function. APOE2 is protective, enhancing amyloid clearance and reducing tau pathology. Therapeutic strategies include APOE4 structure correctors, gene therapy to convert APOE4 to APOE3, and anti-APOE4 antibodies.
| Gene Symbol | APOE |
| Full Name | Apolipoprotein E |
| Chromosome | 19q13.32 |
| Target Class | Ligand |
| Function | It binds to the LDL receptor family to facilitate uptake of lipoprotein particles. |
| Mechanism of Action | Protein-protein interaction modulator or lipid metabolism enhancer |
| Druggability | Medium (0.47) |
| Clinical Stage | Phase II |
| Molecular Weight | 34 kDa |
| Pathways | Amyloid, Autophagy, Blood-Brain Barrier, Brain Lipid Metabolism, Cholesterol |
| GeneCards | APOE |
| Human Protein Atlas | APOE |
| Genotype | AD Risk |
| ε3/ε3 | Baseline (1x) |
| ε3/ε4 | ~3x increased |
| Associated Diseases | AD, AGING, ALS, ALZHEIMER, ALZHEIMER'S DISEASE, AMI |
| Known Drugs/Compounds | LIPOPROTEINS, Triacylglycerol, Lipid-Targeting Therapeutic Strategies |
| Interactions | LRP1, LDLR, LOX, IL6, SREBF1, PSEN2 |
| SciDEX Target | View Target Profile (8 clinical trials) |
| SciDEX Hypotheses | APOE4-Specific Lipidation Enhancement Therapy Prime Editing Precision Correction of APOE4 to APO Selective APOE4 Degradation via Proteolysis Target (+11 more) |
| KG Connections | 4776 knowledge graph edges |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |
Knowledge base pages for this entity
graph TD
APOE["APOE"]
APOE -->|"produces"| microRNAs["microRNAs"]
APOE -->|"activates"| histone_acetylation["histone acetylation"]
APOE -.protects against.-> ferroptosis["ferroptosis"]
APOE -.biomarker for.-> ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"]
APOE -->|"contributes to"| Alzheimer_s_disease["Alzheimer's disease"]
APOE -->|"activates"| MHC_I["MHC-I"]
APOE -->|"causes"| SELECTIVE_NEURODEGENERATION["SELECTIVE NEURODEGENERATION"]
APOE -->|"causes"| lipoprotein_glomerulopathy["lipoprotein glomerulopathy"]
APOE -->|"causes"| neurodegeneration["neurodegeneration"]
APOE -->|"inhibits"| cholesterol_biosynthesis["cholesterol biosynthesis"]
h_b948c32c["h-b948c32c"] -->|"target for"| APOE
h_44195347["h-44195347"] -->|"target for"| APOE
h_d0a564e8["h-d0a564e8"] -->|"target for"| APOE
h_11795af0["h-11795af0"] -->|"target for"| APOE
h_99b4e2d2["h-99b4e2d2"] -->|"target for"| APOE
h_a20e0cbb["h-a20e0cbb"] -->|"target for"| APOE
TREM2["TREM2"] -->|"participates in"| APOE
siRNA["siRNA"] -->|"inhibits"| APOE| Target | Relation | Type | Str |
|---|---|---|---|
| neurodegeneration | implicated_in | disease | 0.50 |
| ad_genetic_risk_loci:APOE | data_in | dataset_row | 0.00 |
| benchmark_ot_ad_answer_key:APOE | data_in | dataset_row | 0.00 |
| Source | Relation | Type | Str |
|---|---|---|---|
| ad_genetic_risk_loci:APOE | data_in | dataset_row | 0.00 |
| benchmark_ot_ad_answer_key:APOE | data_in | dataset_row | 0.00 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
neurodegeneration | 2026-04-16 | 0 hypotheses
neurodegeneration | 2026-04-15 | 0 hypotheses
neurodegeneration | 2026-04-15 | 1 hypotheses Top: 0.544
neurodegeneration | 2026-04-14 | 1 hypotheses Top: 0.505
neurodegeneration | 2026-04-14 | 1 hypotheses Top: 0.588
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegenerat [PMID:37995685] | Litvinchuk A, Suh JH, Guo JL, Lin K, Dav | Neuron | 2024 | 1 |
| The cell biology of APOE in the brain. [PMID:37805344] | Windham IA, Cohen S | Trends Cell Biol | 2024 | 1 |
| The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegene [PMID:37957317] | Maxine R Nelson, Peng Liu, Ayushi Agrawa | Nature neuroscience | 2023 | 1 |
| APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485] | Serrano-Pozo A, Das S, Hyman BT | Lancet Neurol | 2021 | 1 |
| Lysosome-targeting chimaeras for degradation of extracellular proteins. [PMID:32728216] | Banik SM, Pedram K, Wisnovsky S, Ahn G, | Nature | 2020 | 1 |
| Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456] | Long JM, Holtzman DM | Cell | 2019 | 1 |
| Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. [PMID:31367008] | Yamazaki Y, Zhao N, Caulfield TR, Liu CC | Nat Rev Neurol | 2019 | 1 |
| Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associate [PMID:41905188] | Cetindag AC, Schipke CG, Esselmann H, Kr | The journal of prevention of A | 2026 | 0 |
| Perioperative polygenic and APOE-based genetic risk assessment for neurocognitiv [PMID:40562635] | Thedim M, Hu J, Maher M, Wiener-Kronish | Br J Anaesth | 2026 | 0 |
| Increased genetic protection against Alzheimer's disease in centenarians. [PMID:40615639] | Bae H, Song Z, Ali A, Sasaki T, Tesi N e | Geroscience | 2026 | 0 |
| Integrative machine learning approach to risk prediction for dementia and Alzhei [PMID:40864401] | Stern A, Linial M | Geroscience | 2026 | 0 |
| Adipose Tissue Macrophage-Derived Proplatelet Basic Protein Exacerbates Psoriasi [PMID:40886963] | Zhu L, Du L, Wu J, Ding D, Wang J et al. | J Invest Dermatol | 2026 | 0 |
| Restoration of p53 mRNA combined with BRD4 silencing by brain targeted nanocapsu [PMID:41101204] | Sang Y, Cao Y, Li S, Quan Y, Wang S et a | Biomaterials | 2026 | 0 |
| Targeting KAT8 alleviates vascular senescence by modulating the INHBA/TGF-β path [PMID:41445196] | Lin Z, Xiong J, Zhang F, Zhang H, Zhu M | Mol Ther | 2026 | 0 |
| Menopause, cognition, and Alzheimer's disease risk. [PMID:41531227] | Samudra N, Vemuri M, Weitlauf J | Curr Opin Obstet Gynecol | 2026 | 0 |
| ApoE-directed CpG nano-immunoadjuvant ameliorates Alzheimer's-like pathology in [PMID:41651379] | Huang X, Sun YY, Qin YR, Chen H, Pan TT | J Control Release | 2026 | 0 |
| Albofungin vesicle nanobombs trigger lysosomal disruption for self-enhanced pyro [PMID:41679437] | Chen C, Tan S, Zhu X, Song Z, Xing Y et | J Control Release | 2026 | 0 |
| Covalent Bond Locking in Semiconducting Oligomers Boosts Ultrabright NIR-II Lumi [PMID:41757652] | Li X, Gan H, Zhang C, Gao Y, Zhang J et | Angew Chem Int Ed Engl | 2026 | 0 |
| Inflammation-related miR-155-5p as an APOE ε4-modulated biomarker for amyloid pa [PMID:41930593] | Yoshida K, Saito N, Takahashi R, Ando S, | J Alzheimers Dis | 2026 | 0 |
| UBE2I Alleviates Pyroptosis in Coronary Heart Disease by Promoting the SUMOylati [PMID:41930933] | Ding SK | Immunol Invest | 2026 | 0 |